Larry L. Green
Directeur Général chez Ablexis LLC
Profil
Larry L.
Green was the founder of Cell Genesys, Inc. (founded in 1992) where he held the title of Principal from 1992 to 2013.
He is also the founder of Ablexis LLC (founded in 2009) where he currently holds the title of Chief Executive Officer.
In addition, Dr. Green is the founder of AlivaMab Biologics LLC (founded in 2018) where he currently holds the title of Chairman & Chief Executive Officer.
Dr. Green's former job includes being the Chief Executive Officer of Aliva Biopharmaceuticals, Inc. and the Director-Antibody Operations of Abgenix, Inc. Dr. Green's education history includes a doctorate degree from the University of Wisconsin and an undergraduate degree from the University of Kentucky.
Postes actifs de Larry L. Green
| Sociétés | Poste | Début |
|---|---|---|
Ablexis LLC
 Ablexis LLC Packaged SoftwareTechnology Services Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA. | Directeur Général | 03/06/2010 |
AlivaMab Discovery Services LLC
 AlivaMab Discovery Services LLC BiotechnologyHealth Technology AlivaMab Discovery Services LLC is a private company that specializes in generating and screening large panels of antibodies to achieve their partners' design goals. AlivaMab Discovery Services is based in San Diego, CA. The company focuses on delivering antibodies that are characterized for function, kinetics, and developability, and engineering for advanced modalities, including multispecifics and cars. The company has experience in antibody drug discovery and development from many of the world's top pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech. The company was founded by John Lippincott, and the CEO is Larry L. Green. | Directeur Général | 01/01/2018 |
Anciens postes connus de Larry L. Green
| Sociétés | Poste | Fin |
|---|---|---|
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Fondateur | - |
Abgenix, Inc.
 Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Corporate Officer/Principal | - |
Aliva Biopharmaceuticals, Inc.
 Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | President | - |
Formation de Larry L. Green
| University of Wisconsin | Doctorate Degree |
| University of Kentucky | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Health Technology |
Aliva Biopharmaceuticals, Inc.
Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | Health Technology |
AlivaMab Discovery Services LLC
AlivaMab Discovery Services LLC BiotechnologyHealth Technology AlivaMab Discovery Services LLC is a private company that specializes in generating and screening large panels of antibodies to achieve their partners' design goals. AlivaMab Discovery Services is based in San Diego, CA. The company focuses on delivering antibodies that are characterized for function, kinetics, and developability, and engineering for advanced modalities, including multispecifics and cars. The company has experience in antibody drug discovery and development from many of the world's top pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech. The company was founded by John Lippincott, and the CEO is Larry L. Green. | Health Technology |
Ablexis LLC
Ablexis LLC Packaged SoftwareTechnology Services Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA. | Technology Services |
